期刊文献+

伊维菌素小单室脂质体工艺配方优化及质量分析 被引量:2

Optimizing Process and Formula and Analyzing Quality for Ivermectin Single Unilamellar Vesicles
在线阅读 下载PDF
导出
摘要 为获得高包封率的伊维菌素小单室脂质体,本研究对其制备工艺进行了优化,并选取超声波频率、超声时间、卵磷脂与胆固醇质量比、伊维菌素与卵磷脂质量比各因素进行正交交互作用考察,同时利用反相高效液相色谱法对各工艺配方组合下伊维菌素小单室脂质体的包封率进行了测定。结果显示,伊维菌素小单室脂质体的制备最佳配方和工艺组合为超声波频率200kHz,超声时间6min,伊维菌素与大豆卵磷脂质量比为1∶10。经过优化组合,得到了较高品质的伊维菌素小单室脂质体,平均载药量达到(92.35±0.61)%,药物品质优良,且制备工艺简单可行。 To obtain high entrapment rate of ivermectin single unilamellar vesicles. The study was aim to optimizing prepa ration process of ivermectin single unilamellar vesicles; we had selected some factors such as ultrasonic frequency, ultrasonic time, mass ratio of lecithin to cholesterol and mass ratio of ivermectin to lecithin to design orthogonal test L8 (2^7), and we used RP-HPLC to determine the entrapment rate of ivermectin single unilamellar vesicles under every combination of process and formula. The results showed the optimal process and formula combination of ivermectin single unilamellar vesicles were as fol- lows: the ultrasonic frequency was 200 kHz, the ultrasonic time was 6 minutes and the mass ratio of ivermectin to lecithin was 1 : 10. We have obtained high qualitative ivermeetin single unilamellar vesicles by optimization,the loading rate reach (92.35 0.61) %, the quality of drug is fine, the preparation process are simple and feasible.
出处 《中国畜牧兽医》 CAS 北大核心 2012年第7期108-112,共5页 China Animal Husbandry & Veterinary Medicine
基金 西藏自治区科技厅重点项目(NO10-1)
关键词 伊维菌素 小单室脂质体 制剂技术 质量分析 正交试验 ivermectin single unilamellar vesicles prescription and preparation technology quality analyzing orthogonal test
  • 相关文献

参考文献15

二级参考文献178

共引文献185

同被引文献29

  • 1张永清,杨德全,陈裕祥,刘建枝,达扎,次仁玉珍.西藏申扎县家畜寄生虫区系调查报告[J].中国兽医科技,1994,24(3):18-21. 被引量:7
  • 2汪杨,吴伟,阙俐.油-吐温-醇-水体系伪三元相图在自微乳化制剂研究中的应用[J].中国医药工业杂志,2005,36(6):345-348. 被引量:46
  • 3陈新华,邓业成,朱燕红.46种植物提取物对柑橘红蜘蛛的杀螨活性[J].广西师范大学学报(自然科学版),2006,24(1):94-97. 被引量:20
  • 4陈玲,周建平.微乳的处方因素对伊维菌素体外透皮性能的影响[J].中国药学杂志,2006,41(15):1154-1157. 被引量:6
  • 5Chhaiya S B, Mehta D S, Kataria B C. Ivermectin: Pharmacology and therapeutic applications[J]. Inter- national Journal of Basic : Clinical Pharmacolo- gy, 2012,1 (3) : 132-139.
  • 6Shakeel F, Baboota S, Ahuja A. Celecoxib nanoemul- sion for transdermal drug delivery: Characterization and in vitro evaluation[J]. Journal of Dispersion Science and Technology ,2009,30(6):834 842.
  • 7Shafiq S, Shakeel F, Talegaonkar S. Development and bioavailability assessment of rarnipril nanoemulsion formulation[J]. European Journal of Pharmaceutics and Biopharmaceutics ,2007,66(2) :227-243.
  • 8Shakeel F,Shafiq S, Haq N. Nanoemulsions as poten- tial vehicles for transdermal and dermal delivery of hydrophobic compounds [J]. Informa Healthcare, 2012,9(8) :95a-974.
  • 9Zhou H,Wan J L,Wu L,et al. A new strategy for en- hancing the oral bioavailability of drugs with poor wa- ter solubility and low liposolubility based on phospho- lipid complex and supersaturated SEDDS[J]. PLoS 0ne,2013,8(12) :e84530.
  • 10Dixit N, Kohli K, Baboota S. Nanoemulsion system for the transdermal delivery of a poorly soluble cardiovas- cular drug[J]. PDA Journal of Pharmaceutical Sci- ence and Technology, 2008,62 (1) : 46-55.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部